DelveInsight's 'Sporadic Inclusion Body Myositis (sIBM) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Sporadic Inclusion Body Myositis (sIBM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Sporadic Inclusion Body Myositis (sIBM) epidemiology report gives a thorough understanding of the Sporadic Inclusion Body Myositis (sIBM) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Sporadic Inclusion Body Myositis (sIBM) in the US, Europe, and Japan. The report covers the detailed information of the Sporadic Inclusion Body Myositis (sIBM) epidemiology scenario in seven major countries (US, EU5, and Japan).
The Sporadic Inclusion Body Myositis (sIBM) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Sporadic Inclusion Body Myositis (sIBM) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Sporadic Inclusion Body Myositis (sIBM) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Sporadic Inclusion Body Myositis (sIBM) epidemiology covered in the report provides historical as well as forecasted Sporadic Inclusion Body Myositis (sIBM) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Sporadic Inclusion Body Myositis (sIBM) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Sporadic Inclusion Body Myositis (sIBM)
3. Sporadic Inclusion Body Myositis (sIBM): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Sporadic Inclusion Body Myositis (sIBM) Treatment and Management
6.2. Sporadic Inclusion Body Myositis (sIBM) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in 7MM (2017-2030)
Table 2 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in the United States (2017-2030)
Table 4 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Germany (2017-2030)
Table 6 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in France (2017-2030)
Table 8 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Italy (2017-2030)
Table 10 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Spain (2017-2030)
Table 12 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in the United Kingdom (2017-2030)
Table 14 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Japan (2017-2030)
Table 16 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in 7MM (2017-2030)
Figure 2 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in the United States (2017-2030)
Figure 4 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Germany (2017-2030)
Figure 6 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in France (2017-2030)
Figure 8 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Italy (2017-2030)
Figure 10 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Spain (2017-2030)
Figure 12 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in the United Kingdom (2017-2030)
Figure 14 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Japan (2017-2030)
Figure 16 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report